Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.55 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.55 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14378641 | 1.00 | EGFR (0.55) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL310447 | 1.00 | EGFR (0.55) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL9365545 | 0.85 | EGFR (0.61) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL9365540 | 0.85 | EGFR (0.61) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL13919924 | 0.84 | ALDH1A1 (0.62) | KDM4EALDH1A1HPGD | |
| SCHEMBL13037033 | 0.84 | MAPT (0.57) | EGFRCISD1KDM4EALDH1A1CYP3A4 | |
| SCHEMBL8965681 | 0.82 | ALDH1A1 (0.50) | EGFRKDM4EALDH1A1CYP3A4HPGD | |
| SCHEMBL28093619 | 0.82 | ALDH1A1 (0.74) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL5550763 | 0.81 | EGFR (0.59) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL11369353 | 0.81 | EGFR (0.59) | EGFRCISD1KDM4ESLC16A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1481244-A2 | MONOMERS AND POLYMERS HAVING ENERGY ABSORBING MOIETIES OF USE IN DESORPTION/IONIZATION OF ANALYTES | Ciphergen Biosystems, Inc. (US) | 2004-12-01 | — | — | EP | claimed |
| US-20030207462-A1 | Monomers and polymers having energy absorbing moieties of use in desorption/ionization of analytes | CIPHERGEN BIOSYSTEMS, INC. | 2003-11-06 | — | — | US | claimed |
| US-20030207460-A1 | Monomers and polymers having energy absorbing moieties of use in desorption/ionization of analytes | CIPHERGEN BIOSYSTEMS, INC. | 2003-11-06 | — | — | US | claimed |
| WO-2003064594-A2 | MONOMERS AND POLYMERS HAVING ENERGY ABSORBING MOIETIES OF USE IN DESORPTION/IONIZATION OF ANALYTES | CIPHERGEN BIOSYSTEMS, INC. (US) | 2003-08-07 | — | — | WO | claimed |
| US-20230233645-A1 | EFFECTIVE TREATMENTS FOR VASCULAR ASSOCIATED MACULOPATHY, SEVERE MACULOPATHY, LATE-STAGE MACULOPATHY, AND ABERRANT CHORIOCAPILLARIS | UNIV UTAH RES FOUND (US) | 2023-07-27 | — | — | US | disclosed |
| EP-4185301-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING HIGH GRADE SUBTYPES OF UTERINE CANCER | The Regents Of The University Of Michigan (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220317126-A1 | BIOMARKERS FOR OVARIAN CANCER CTAP3-RELATED PROTEINS | ASPIRA WOMEN'S HEALTH INC. (US) | 2022-10-06 | — | — | US | disclosed |
| US-11371993-B2 | Autoantibody biomarkers of ovarian cancer | ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) | 2022-06-28 | — | — | US | disclosed |
| CN-105823877-B | Biomarkers for ovarian cancer: CTAP 3-related protein | 约翰·霍普金斯大学 | 2022-02-25 | — | — | CN | disclosed |
| US-11255857-B2 | Biomarkers for ovarian cancer CTAP3-related proteins | ASPIRA WOMEN'S HEALTH INC. (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2022020359-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING HIGH GRADE SUBTYPES OF UTERINE CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-27 | — | — | WO | disclosed |
| US-20210353712-A1 | METHODS OF DIAGNOSING AND TREATING VASCULAR ASSOCIATED MACULOPATHY AND SYMPTOMS THEREOF | UNIV UTAH RES FOUND (US) | 2021-11-18 | — | — | US | disclosed |
| US-20040029191-A1 | Detection of kinase substrates and products using ion mass spectrometry | CIPHERGEN BIOSYSTEMS, INC. | 2004-02-12 | — | — | US | disclosed |
| WO-2004009798-A2 | PROTEIN INTERACTION DIFFERENCE MAPPING | CIPHERGEN BIOSYSTEMS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2003102542-A2 | COMPARATIVE PROTEOMICS OF PROGRESSOR AND NONPROGRESSOR POPULATIONS | CIPHERGEN BIOSYSTEMS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003101394-A2 | DEFENSINS: USE AS ANTIVIRAL AGENTS | CIPHERGEN BIOSYSTEMS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003097867-A1 | DETECTION OF KINASE SUBSTRATES AND PRODUCTS USING ION MASS SPECTROMETRY | CIPHERGEN BIOSYSTEMS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030207462-A1 | Monomers and polymers having energy absorbing moieties of use in desorption/ionization of analytes | CIPHERGEN BIOSYSTEMS, INC. | 2003-11-06 | — | — | US | disclosed |
| US-20030207460-A1 | Monomers and polymers having energy absorbing moieties of use in desorption/ionization of analytes | CIPHERGEN BIOSYSTEMS, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2003064594-A2 | MONOMERS AND POLYMERS HAVING ENERGY ABSORBING MOIETIES OF USE IN DESORPTION/IONIZATION OF ANALYTES | CIPHERGEN BIOSYSTEMS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |